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Abstract  
Objective: Compared with tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) has 
been associated with improvement in markers of renal dysfunction in individual randomised trials; 
however the comparative incidence of clinically significant renal events remains unclear.  
Design: We used a pooled data approach to increase the person-years of drug exposure analysed, 
maximizing our ability to detect differences in clinically significant outcomes. 
Methods: We pooled clinical renal safety data across 26 treatment naïve and antiretroviral switch 
studies in order to compare the incidence of proximal renal tubulopathy (PRT) and discontinuation 
due to renal adverse events (AEs) between participants taking TAF-containing regimens versus those 
taking TDF-containing regimens. We performed secondary analyses from seven large randomised 
studies (two treatment-naïve and five switch studies) to compare incidence of renal AEs, treatment-
emergent proteinuria, changes in serum creatinine, creatinine clearance, and urinary biomarkers 
(albumin, beta-2-microglobulin, and retinol binding protein to creatinine ratios). 
Results: Our integrated analysis included 9,322 adults and children with HIV (n=6360 TAF, n=2962 
TDF) with exposure of 12,519 person-years to TAF and 5947 to TDF. There were no cases of PRT in 
participants receiving TAF versus 10 cases in those receiving TDF (p<0.001), and fewer individuals 
on TAF (3/6360) versus TDF (14/2962) (p<0.001) discontinued due to a renal AE. Participants 
initiating TAF- vs. TDF-based regimens had more favourable changes in renal biomarkers through 96 
weeks of therapy.  
Conclusion: These pooled data from 26 studies, with over 12,500 person-years of follow-up in 
children and adults, support the comparative renal safety of TAF over TDF. 
Keywords:  Human Immunodeficiency Virus; Highly Active Antiretroviral Therapy; Tenofovir 
Disoproxil Fumarate; Adverse Drug Event; Proximal Renal Tubular Dysfunction; Renal Fanconi 
Syndrome; Drug Safety Biomarkers 
Introduction 
Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor that is 
highly efficacious and generally well tolerated.  However, TDF is associated with renal 
adverse events (AEs), including proximal renal tubulopathy (PRT), which occurs in less than 
1% of individuals.[1,2] Tenofovir alafenamide (TAF), a tenofovir (TFV) prodrug, is 
associated with a mean 91% lower plasma TFV exposure compared with TDF.[3] As higher 
plasma TFV levels have been associated with nephrotoxicity,[4,5] reduced circulating TFV 
levels are hypothesized to result in fewer renal AEs. In Phase 2 and 3 clinical trials of both 
treatment-naïve and virologically suppressed adults and children,[6-36] TAF-containing 
regimens have demonstrated high efficacy and favorable changes in renal biomarkers 
including creatinine clearance (CrCl), total and tubular proteinuria, and albuminuria 
compared to a variety of unboosted and ritonavir (RTV)- or cobicistat (COBI)-boosted TDF-
containing regimens. It has been more challenging to determine whether the favorable 
biomarker profile of TAF translates into improved renal clinical outcomes, due to the low 
rates of renal events in individual trials, although the 144 week follow up of the pooled 
pivotal trials for elvitegravir (EVG)/ COBI/emtricitabine (FTC)/TAF had zero cases of PRT 
and zero renal discontinuations compared to four cases of PRT and 12 renal discontinuations 
in the EVG/COBI/FTC/TDF group.[8] In order to better understand the renal clinical 
outcomes in TAF versus TDF-containing HIV regimens, we conducted a large integrated 
analysis of people living with HIV (PLH) from 26 TAF clinical trials. These trials included 
cumulative exposures of 12,519 person-years to TAF and 5947 person-years to TDF, thereby 
providing increased statistical power to evaluate the comparative impact on renal AEs and 
renal function over time. 
Methods 
Study design and participants 
We included 26 phase 2 and 3 multicenter, multinational, clinical studies of TAF-containing 
regimens in PLH including adults, adolescents, and children (aged ≥6 years) who were either 
ART-naïve or virologically suppressed on a stable ART regimens containing TDF. These 
studies were conducted between December 28, 2011 and December 4, 2017. Study design 
and inclusion criteria, including minimum renal function, of each trial are described in 
Appendix Table 1. Of the 26 studies, 14 were double blinded and randomised, six were open 
label and randomised, and six were single arm. All trials were undertaken in accordance with 
the Declaration of Helsinki and approved by central or site-specific review boards or ethics 
committees. All participants or their legal guardians (if minors) provided written, informed 
consent. 
Procedures 
Post-baseline study visits were conducted at weeks 4, 8, 12, 24, 36, and 48 and every 12 
weeks thereafter until week 96. Renal laboratory tests included serum creatinine, creatinine 
clearance (CrCl) by Cockcroft-Gault, treatment-emergent proteinuria by dipstick, urine 
albumin to creatinine ratio (UACR), and tubular proteinuria [urine retinol binding protein to 
creatinine ratio (RBP:Cr) and β2-microglobulin to creatinine ratio (β2M:Cr)] (Covance 
Laboratories, Indianapolis, IN, USA). 
Renal safety was assessed by recording of AEs, which were coded by the Investigator using 
the Medical Dictionary for Regulatory Activities (MedDRA, version 18.1 to 19.1) (Appendix 
Table 2). 
Analysis of primary renal safety outcomes 
The primary renal safety outcomes were 1) incidence of PRT events, and 2) study drug renal 
discontinuation events.  For primary outcomes analysis, we pooled all participants from the 
26 available trials who received at least one dose of study drug (safety analysis set). We 
derived safety measures data using all data collected on or after study drug was first given up 
to either the data cut date for participants still on study drug or up to 30 days after the last 
dose of study drug for participants who permanently discontinued treatment early.  We 
summarised baseline demographics and characteristics of the included participants with 
descriptive statistics. 
We defined ‘renal discontinuation events’ as investigator-reported discontinuation events for 
which the attributable MedDRA code exists in selected renal preferred terms from the “Renal 
and urinary disorders” System Organ Class (Appendix Table 2). Similarly, PRT cases were 
defined as investigator-reported AEs indicative of tubular disorders, including reported terms 
of proximal renal tubulopathy and Fanconi syndrome (preferred terms are provided in 
Appendix Table 3), regardless of study drug relatedness. The cumulative incidence rates of 
investigator-reported cases of PRT and renal AEs leading to study drug discontinuation were 
calculated as the number of events divided by the total numbers of participants pooled from 
the 26 trials treated with TAF- or TDF-containing regimens, respectively. The differences in 
the cumulative incidence rates between treatment groups were compared using Fisher’s exact 
test. To minimize type I error resulting from multiple hypothesis testing, we performed 
primary endpoint analysis in a pre-determined sequence, only proceeding to the second 
endpoint (renal discontinuation events) if the first endpoint (PRT events) analysis 
demonstrated statistical significance with α=0.05.   
Analysis of secondary renal outcomes 
We assessed secondary renal outcomes including treatment-emergent renal AEs, serum 
creatinine (SCr), CrCl, treatment-emergent gross proteinuria (by dipstick), urine albumin-to-
creatinine ratio (UACR), and tubular proteinuria (urine RBP:Cr and β2M:Cr).  Treatment-
emergent proteinuria was defined as 1+ or greater proteinuria by dipstick on any occasion 
during trial follow-up, regardless of persistence. Urine protein-to-creatinine ratio was 
monitored during the trials, but a change in assay methodology occurring partway through 
several trials resulted in data unsuitable for integrated analysis. For the analysis of these 
secondary renal outcomes, we selected a subset of trials that satisfied the following pre-
determined criteria: 1) randomized design; 2) TAF and TDF arms; and 3) at least 48 weeks of 
follow-up. Based on these criteria, a total of seven trials were selected, including two 
treatment naïve studies and five virologically suppressed studies (referred to as switch 
studies) (Figure 1). To facilitate accurate assessment of CrCl changes in study participants, 
we excluded participants who switched from an ART regimen lacking a known creatinine 
transport inhibitor to a regimen containing a known creatinine transport inhibitor (rilpivirine, 
dolutegravir, bictegravir, COBI, or ritonavir).[37-42] This approach allowed us to reduce 
confounding caused by SCr increases attributable to initiation of a creatinine transport 
inhibitor.  
Using these data, we evaluated the incidence rates of treatment-emergent renal AEs 
(Appendix Table 2) and of proteinuria by dipstick. We also summarized change from 
baseline in serum creatinine and CrCl and percentage change from baseline in UACR, 
RBP:Cr, and β2M:Cr. We used logistic regression models to compare the differences in 
incidence rates between treatment groups and linear regression and rank analysis of 
covariance (adjusted for baseline demographics and disease characteristics selected from 
step-wise procedure) for change and percentage change from baseline in renal parameters, 
respectively. 
To control for type I error in the testing of multiple secondary renal outcomes hypotheses, we 
employed the following testing strategies. First, the primary comparisons of PRT and renal 
discontinuation events in all 26 studies were analyzed using a pre-defined sequence as 
described above. Subsequently, hypothesis testing for secondary outcomes was performed 
using the Holm-Bonferroni method; p values reported in the text and figures are Holm-
Bonferroni adjusted.[43,44] We used SAS® Software Version 9·4 (SAS Institute Inc., Cary, 
NC, U.S.) for all analyses. All studies were conducted according to protocol without 
substantial deviations. 
Results 
We included a collective 9,322 individuals across 26 studies (Appendix Table 1). Participants 
either initiated or switched to regimens containing TAF (n=6360) or initiated or continued on 
regimens containing TDF (n=2962) (Table 1). Baseline median age was 42 years, 21% were 
women, and 27% were of black race. Pooled data included exposure of 12,519 person-years 
to TAF and 5947 person-years to TDF. 
Primary analyses 
Incidence of PRT events  
In the dataset including all 26 studies, 14 of which were double blinded, there were no cases 
of PRT or Fanconi syndrome reported in the TAF group (Figure 2). Ten cases of PRT, 
including Fanconi syndrome, were reported by site investigators for the TDF group (0.34% of 
participants, p<0.001 vs. TAF). Of the PRT cases, nine of ten were investigator reported as 
study drug-related, nine of ten occurred during blinded therapy, and eight of ten resulted in 
study drug discontinuation. Appendix Figure 1 shows the specific ART regimens, duration of 
study drug exposure relative to onset of PRT and relatedness to study drug as determined by 
the site investigator. The timing of PRT development was variable but often occurred well 
into therapy, including three of ten cases developing in participants who were virologically 
suppressed on TDF for at least six months at the time of enrolment (Appendix Figure 1).  
Discontinuations due to renal AEs  
In the dataset including all 26 studies, three of 6360 individuals (0.05%) who received TAF 
discontinued study drug due to renal AEs compared with 14 of 2962 (0.47%) participants in 
the TDF group (p<0.001) (Figure 2). Of the 14 participants in the TDF group, four were in 
open-label studies and the remainder were in double-blinded studies; twelve of fourteen 
discontinuations were reported as study drug-related.  All three participants in the TAF group 
were enrolled in open-label studies, and no discontinuations were reported as study-drug 
related. Appendix Figure 2 shows the specific ART regimens, duration of study drug 
exposure relative to onset of the renal AE, as well as relatedness to the study drug as 
determined by the investigator. Appendix Table 4 provides clinical narratives describing the 
renal discontinuation events. 
Secondary analyses 
We next sought to compare secondary renal outcomes between TAF-based and TDF-based 
regimens both in the settings of treatment-naïve ART initiation and regimen switch in 
virologically suppressed PLH. To this end, we identified two ART-naïve studies and five 
switch studies that were randomized, included both TAF and TDF arms, and included at least 
48 weeks of follow-up (Figure 1).  
Total of all renal AEs in ART-naïve PLH 
Based on pooled data from two randomised, double-blinded studies of treatment-naïve PLH, 
clinical renal AEs through week 96 were reported significantly less frequently in the TAF 
group than in the TDF group [47/866 (5.4%) vs. 74/867 (8.5%), p=0.042].  
Changes in renal laboratory parameters and biomarkers in ART-naïve PLH 
In treatment-naïve PLH, median change from baseline at weeks 48 and 96 in serum creatinine 
was significantly lower in the TAF group compared with TDF group (difference in least 
squares mean [LSM] -0.03 mg/dL, p≤0.001 at week 96) (Figure 3A). Similarly, we noted that 
median CrCl had declined less in the TAF group compared to the TDF group (difference in 
LSM 6.0 mL/min, p≤0.001 for week 96) (Figure 3B). 
In treatment-naïve PLH, we observed that treatment-emergent proteinuria at week 96 
(defined as 1+ or greater proteinuria by dipstick on any occasion) was reported for fewer 
people in the TAF group compared with those in the TDF group [307/862; (36%) vs. 354/865 
(41%); p=0.034]. 
Treatment-naïve PLH initiating TAF-based regimens had greater decreases or smaller 
increases from baseline through week 96 in median urinary biomarkers (UACR, RBP:Cr, 
β2M:Cr) compared with TDF (Figure 4). At week 96, median UACR decreased by 5.2% with 
TAF vs. an increase of 4.9% with TDF (p≤0.001) (Figure 4A). Median RBP:Cr increased by 
13.8% with TAF compared with an increase of 74.2% on TDF (p≤0.001) (Figure 4B). 
Median β2M:Cr declined by 32.1% with TAF compared with an increase of 33.5% on TDF 
(p≤0.001) (Figure 4C). 
Total of all renal AEs in virologically suppressed PLH 
We evaluated pooled data from five randomised studies (two open-label, three blinded) of 
virologically suppressed PLH who switched from TDF- to TAF-containing regimens or 
continued their baseline TDF-based regimen. We observed no difference in the rate of 
reported clinical renal AEs in these switch studies [114/2291 (5%) vs. 89/1801 (5%), 
p=1.00].  
Changes in renal biomarkers in virologically suppressed PLH 
For virologically suppressed PLH, there was a greater reduction in median serum creatinine 
from baseline in the TAF group compared with the TDF group (difference in LSM -0.03 
mg/dL, p≤0.001 for week 96) (Figure 3A). Median CrCl increased in the TAF group while no 
change was seen in the TDF group (difference in LSM 5.2 mL/min, p≤0.001 for week 96) 
(Figure 3B). 
In virologically suppressed PLH, we observed that treatment-emergent proteinuria at week 96 
(defined as 1+ or greater proteinuria by dipstick on any occasion) was reported for fewer 
people in the TAF group compared with those in the TDF group [636/2287 (28%) vs. 
561/1794 (31%); p=0.04]. 
In virologically suppressed participants switching from TDF to TAF, TAF-based regimens 
had greater decreases or smaller increases from baseline through week 96 in median renal 
biomarkers (UACR, RBP:Cr, β2M:Cr) compared with TDF (Figure 4). Median UACR 
decreased by 5.4% on TAF and increased by 27.0% on TDF (p≤0.001) (Figure 4A). Median 
RBP:Cr decreased by 2.3% on TAF and increased 61.2% on TDF (p≤0.001) (Figure 4B). 
Median β2M:Cr decreased by 25.8% with TAF and increased by 53.0% on TDF (p≤0.001) 
(Figure 4C). 
Discussion 
Previous studies have demonstrated more favourable renal biomarker profiles in TAF-
containing regimens compared to TDF-containing regimens; however the sample sizes of 
individual trials and the overall low rate of clinically significant renal AEs in these trials 
limited the ability to detect differences in the rates of these events with the exception of the 
pooled pivotal EVG trials. In the present analysis, we integrated data from 26 individual trials 
and were able to demonstrate the renal safety of TAF over TDF across a broad range of PLH, 
including those who were treatment naïve and those who were virologically suppressed at 
switch. After 12,519 person-years of exposure to TAF, there were no cases of PRT or 
Fanconi syndrome (identified objectively and independently by the primary investigator 
caring for the participant) and significantly fewer discontinuations due to renal AEs in the 
TAF group compared with the TDF group. Notably, only three (0.02%) renal discontinuation 
events were reported in participants on TAF; none of these were reported as study drug-
related by the investigators, and all had plausible alternative aetiologies. 
In treatment naïve participants, we observed fewer overall renal AEs in participants taking 
TAF containing regimens compared to those taking TDF containing regimens. No difference 
in overall renal AEs was observed in participants enrolled in switch studies; this may be 
explained by the fact that participants in those studies were already maintained on TDF at the 
time of enrolment, and thus self-selected as less likely to develop renal AEs. 
By using an integrated analysis, we were able to demonstrate favourable changes in renal 
biomarkers in participants taking TAF containing regiments compared to those taking TDF, 
both in treatment naïve and treatment experienced patients who switched to TAF containing 
regimens. Our findings demonstrate favourable changes in creatinine clearance as well as in 
proximal tubule function (RBP and β2M ratios). We also observed a lower incidence of 
treatment-emergent proteinuria in participants taking TAF containing regimens.  The 
observed incidences of proteinuria were high, but notably these are cumulative incidences 
over 96 weeks of follow-up, and are consistent with previously reported incidences of 
proteinuria in PLH.[45] These biomarker findings in combination with the clinical outcomes 
suggest that TAF does not induce proximal tubule dysfunction.  
The mechanism for the improved renal safety profile of TAF is likely related to the 
approximately 90% lower plasma levels of TFV seen in participants receiving TAF compared 
to those receiving TDF. This mechanism is supported by the reported association between 
declines in renal tubular function and higher TFV plasma concentrations.[46-48] 
Conversely, the use of boosting agents such as RTV and COBI increase TFV exposure, and 
accordingly the use of boosting agents has been associated with an increased risk of renal 
AEs.[49,50] A recent meta-analysis sought to compare the renal safety profiles of TDF 
containing regimens in the presence and absence of boosting agents, and suggested that 
unboosted TDF could have a similar renal safety profile as TAF.[49] However, the 
aforementioned meta-analysis is limited by a relatively small number of participants and 
short duration of follow-up. In the findings presented here, nine out of ten PRT cases 
occurred in participants receiving boosted regimens; however one severe case of PRT 
occurred in a participant receiving TDF without a boosting agent. Our data support the 
principle that boosting agents increase the risk of TFV-associated renal AEs, however our 
ability to make robust conclusions about the renal safety of unboosted TDF is limited by the 
comparatively small number of participants taking such regimens (of 9322 total participants, 
2962 were on TDF, and of those 1101 were on TDF without a boosting agent). While the 
question of renal safety of TDF in unboosted regimens warrants more evaluation, the 
available data indicate that TAF can be safely used with boosted as well as unboosted third 
agents with a very low incidence of clinically significant renal events. 
We note several limitations to our analyses. It is challenging to diagnose PRT, and no 
commonly accepted single diagnostic exists in the clinic to confirm PRT. As such, we 
utilized investigator-reported events to document PRT, which may have underestimated the 
number of PRT cases. A reporting bias is possible given the use of investigator reported 
events, but is unlikely to have affected our findings since most of the included trials were 
double-blinded, and the majority of reported renal discontinuation events and PRT cases were 
reported during blinded trial phases. Our clinical trial participants may have been healthier 
than the general population of PLH due to the presence of inclusion and exclusion criteria in 
the trials, although TAF was found to safe in patients with impaired renal function (CrCl 30-
70 mL/min, many of whom with diabetes mellitus, hypertension and proteinuria), with no 
reported cases of PRT and overall stable renal function through 96 weeks of follow up.[51] 
We also acknowledge that we did not have individual level data on the duration of prior TDF 
therapy in our trials and therefore could not adjust the rates accordingly. 
Despite these limitations, the integrated analysis presented here is based on the large 
cumulative exposure in person-years to TAF, both in antiretroviral naïve and virally 
suppressed populations. Furthermore, the pooled data used for analysis includes a 
demographically diverse population with a wide age range, a large number of women and 
diverse ethnic background. It is also notable that a proportion of participants had relatively 
low CrCl, with variable CrCl eligibility cut-offs of 30, 50, or 70 mL/min in the trials included 
in this analysis (Appendix Table 1). The clinical trial data are supported by experience from 
the post-approval use in PLH where currently there has been no renal safety signal with 1.1 
million cumulative person-years exposure to TAF.  
In conclusion, the pooled data from 26 clinical studies, representing over 12,500 patient-years 
of follow-up in children and adults on TAF, suggests that the favourable renal biomarker 
profile observed with TAF vs. TDF in the individual trials translates into a lower rate of 
clinically significant renal events. These data support a comparative renal safety advantage of 
TAF over TDF in a broad range of PLH. 
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Captions 
Figure 1.  Characteristics of studies included in the integrated analysis.  Treatment naïve 
studies included in the secondary analysis are highlighted in blue, virologically suppressed 
PLH studies are highlighted in green.  3TC, lamivudine; ATV, atazanavir; AE, adverse event; 
B, BIC, bictegravir; C, COBI, cobicistat; DRV, darunavir; DTG, dolutegravir; DB, double 
blind; E, elvitegravir; FTC, emtricitabine; OL, open label; PI, protease inhibitor; R, 
randomized; R, RPV, rilpivirine; RTV, ritonavir; STR, single tablet regimen; TE, treatment-
experienced; TN, treatment-naïve; VS, virologically suppressed 
Figure 2.  Cases of proximal renal tubulopathy and renal AEs leading to study drug 
discontinuation across 26 clinical studies.  The incidence of PRT and renal discontinuation 
events were determined using pooled data from 26 studies as described in the Methods 
section. Differences between treatment groups compared using Fisher exact test. 
Figure 3.  Longitudinal changes in renal laboratory parameters.  Serum creatinine (A) 
and creatinine clearance (B) were determined longitudinally as described in the methods 
section, and are depicted as median change from baseline (purple = tenofovir alafenamide, 
orange = tenofovir disoproxil fumarate).  In each panel, the first plot depicts pooled data from 
2 treatment naïve studies, and the second plot depicts data from 5 virologically suppressed 
studies. Differences between treatment groups in changes from baseline were compared using 
linear regression (baseline demographics and disease characteristics selected from step-wise 
procedure adjusted). 
Figure 4.  Longitudinal changes in renal biomarkers.  UACR (A), RBP:Cr ratio (B), and 
β2M:Cr ratio (C) were determined longitudinally as described in the methods section and are 
depicted as median percent change from baseline (purple = tenofovir alafenamide, orange = 
tenofovir disoproxil fumarate). In each panel, the first plot depicts pooled data from 2 
treatment naïve studies, and the second plot depicts data from 5 virologically suppressed 
studies. Differences between treatment groups in changes from baseline were compared using 
linear regression (baseline demographics and disease characteristics selected from step-wise 
procedure adjusted). 
Table 1. Baseline demographic and clinical characteristics 
Characteristic 
TAF 
(N=6360) 
TDF 
(N=2962) 
Total 
(N=9322) 
Age (years) 41 (7, 80) 42 (18, 79) 42 (7, 80) 
Sex 
Male 4966 (78%)  2436 (82%) 7402 (79%) 
Female 1394 (22%)  526 (18%) 1920 (21%) 
Race 
White 3796 (60%)  1884 (64%) 5680 (61%) 
Black 1799 (28%)  739 (25%) 2538 (27%) 
Asian 373 (6%)  181 (6%) 554 (6%) 
Other 376 (6%)  153 (5%) 529 (6%) 
Declined to respond 16 (<1%)  5 (<1%) 21 (<1%) 
Ethnicity Hispanic or Latino 1188 (19%) 537 (18%) 1725 (19%) 
Treatment 
status 
Naive 2191 (34%)  975 (33%) 3166 (34%) 
Experienced 4169 (66%)  1987 (67%) 6156 (66%) 
CrCl  (mL/min) 108.8 (91.2, 129.6) 107.7 (90.9, 128.4) 108.6 (91.1, 129.3) 
Data are median (IQR) or n (%), except for age, which is median (range). 
CrCl, creatinine clearance   
